| | 证券代码 | 训 - | 年涨跌幅 | | | --- | --- | --- | --- | --- | | | | | ［交易日期］最新收盘日 | | | | | | [单位] % ↓ | | | 1 | 300986.SZ | : 志特新材 | | 198.5689 | | 2 | 301079.SZ | 邵阳液压 | | 121.8918 | | 3 | 920207.BJ | 众诚科技 | | 85.7143 | | ব | 688031.SH | 星环科技-U | | 79.6839 | | 5 | 300058.SZ | 蓝色光标 | | 78.9931 | | 1 6 | 002931.SZ | 锋龙股份 | | 77.1924 | | 7 . | 002519.SZ | 银河电子 | | 77.0062 | | 8 in | 688258.SH | 卓易信息 | | 72.2346 | | 9 | 002202.SZ | 金风科技 | | 72.2059 | | 10 | 002173.SZ | 创新医疗 | | 71.9665 | 编辑｜钉钉 1月12日晚间，志特新材公告，公司股票 ...

Core Viewpoint - The company, Innovation Medical (002173.SZ), has noted increased market attention on its brain-computer interface business, particularly through its subsidiary, Boling Brain Machine (Hangzhou) Technology Co., Ltd. [1] Group 1: Company Overview - Boling Brain Machine was established in early 2021 and is expected to be included in the company's consolidated financial statements by August 2025 [1] - The primary products are designed for rehabilitation training of patients with cerebrovascular diseases, mainly focusing on stroke and hemiplegia [1] Group 2: Product Development and Financial Performance - The product "Cyberlink AC5" was officially launched in October 2025, generating revenue of 114,000 yuan in that year [1] - The "Cyberlink AM5" has completed multi-center clinical trials but has not generated revenue in 2025 [1] - The operating losses for Boling Brain Machine were 6.60 million yuan in 2023 and 8.66 million yuan in 2024 [1]

Core Viewpoint - Innovation Medical (002173) has experienced significant stock price fluctuations, with a cumulative increase of over 20% in closing prices over three consecutive trading days, indicating heightened market interest in the company's brain-computer interface business [1] Group 1: Stock Performance - The company's stock price showed abnormal volatility on January 8, 9, and 12, with a cumulative price deviation exceeding 20% [1] - This fluctuation is in accordance with the trading rules of the Shenzhen Stock Exchange, categorizing it as an abnormal trading situation [1] Group 2: Business Overview - The company's subsidiary, Boling Brain Machine (Hangzhou) Technology Co., Ltd., was established in early 2021 and is focused on brain-computer interface products [1] - The primary applications of Boling Brain Machine's products are for rehabilitation training of patients with cerebrovascular diseases, particularly those suffering from stroke-related paralysis [1] - The product "Cyberlink AC5" was officially launched in October 2025, generating revenue of 114,000 yuan in that year [1] - The "Cyberlink AM5" has completed multi-center clinical trials but has not yet generated revenue as of 2025 [1] Group 3: Financial Performance - Boling Brain Machine reported operating losses of 6.6017 million yuan in 2023 and 8.6641 million yuan in 2024 [1]

Core Viewpoint - The company, Innovation Medical, has noted increased market attention on its brain-computer interface business, particularly through its subsidiary, Boling Brain Technology [1] Group 1: Company Overview - Boling Brain Technology was established in early 2021 and is expected to be included in the company's consolidated financial statements by August 2025 [1] - The primary products are designed for rehabilitation training of patients with cerebrovascular diseases, mainly focusing on stroke and hemiplegia [1] Group 2: Product Development and Financial Performance - The product "Cyberling Science AC5" was officially launched in October 2025, generating revenue of 114,000 yuan in that year [1] - The "Cyberling Science AM5" has completed multi-center clinical trials but has not generated revenue in 2025 [1] - The operating losses for Boling Brain Technology were 6.6017 million yuan in 2023 and 8.6641 million yuan in 2024 [1]

Core Viewpoint - The company has noted increased market attention on its brain-computer interface business, particularly through its subsidiary, Boling Brain Technology (Hangzhou) Co., Ltd, which was established in early 2021 and included in the consolidated financial statements in August 2025 [1] Group 1: Company Overview - Boling Brain Technology focuses on rehabilitation training for patients with cerebrovascular diseases, primarily targeting stroke and hemiplegia patients, both in medical institutions and at home [1] - The product "Cyberlink AC5" was officially launched in October 2025, generating revenue of 114,000 yuan in that year [1] - The "Cyberlink AM5" product has completed multi-center clinical trials but has not yet generated revenue as of 2025 [1] Group 2: Financial Performance - The operating losses for Boling Brain Technology were 6.60 million yuan in 2023 and 8.66 million yuan in 2024 [1]

证券代码：002173 证券简称：创新医疗 公告编号：2026-002 创新医疗管理股份有限公司 股票交易异常波动公告 5、公司不存在违反公平信息披露规定的其他情形。 6、公司控股股东及实际控制人在本公司股票交易异常波动期间未买卖本公 司股票。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 创新医疗管理股份有限公司（以下简称"公司"）股票（证券简称：创新医 疗，股票代码：002173）于2026年1月8日、9日、12日连续三个交易日内日收盘 价格涨幅偏离值累计超过20%，根据《深圳证券交易所交易规则》的有关规定， 公司股票属于交易异常波动的情形。 二、公司关注、核实情况的说明 针对公司股票交易异常波动情况，公司对控股股东及实际控制人、公司董事 及高级管理人员就相关问题进行了核实，现将有关情况说明如下： 1、公司前期披露的信息不存在需要更正、补充之处。 2、公司未发现近期公共传媒报道了可能或已经对本公司股票交易价格产生 较大影响的未公开重大信息。 3、近期公司生产经营情况及内外部经营环境未发生重大变化。 4、公司、控股股东及实际 ...

Core Viewpoint - Innovation Medical (002173) has experienced a significant stock price increase, with a cumulative deviation of over 20% in closing prices over three consecutive trading days [1] Group 1: Company Performance - The company's subsidiary, Boling Brain Machine, launched the Cyberlink AC5 product in October 2025, generating revenue of 114,000 yuan in 2025 [1] - The Cyberlink AM5 product has completed multi-center clinical trials but has not generated revenue in 2025 [1] - The operating losses for Boling Brain Machine were 6.60 million yuan in 2023 and 8.66 million yuan in 2024 [1]

Core Viewpoint - The company's stock experienced an abnormal fluctuation with a cumulative closing price increase exceeding 20% over three consecutive trading days in January 2026, despite no significant changes in its operations or external environment [1] Group 1: Stock Performance - The stock price deviation occurred on January 8, 9, and 12, 2026, indicating unusual market activity [1] - The company confirmed that there were no corrections or supplementary disclosures to previously released information [1] Group 2: Business Operations - The company noted high market interest in its brain-computer interface business [1] - The subsidiary, Boling, launched the Cyberlink AC5 product in October 2025, generating revenue of 114,000 yuan in 2025 [1] - The Cyberlink AM5 product did not generate any revenue, and Boling is expected to incur operating losses in 2023 and 2024 [1] Group 3: Investor Advisory - The company advised investors to make rational investment decisions in light of the stock's volatility and the current business performance [1]

Core Viewpoint - The company has received formal notification from the National Medical Products Administration confirming that its Concave Supra integrated arch branch reconstruction system (CSTM stent system) has entered the special review procedure for innovative medical devices, marking a significant advancement in minimally invasive treatment for complex aortic arch aneurysms and penetrating ulcers [1][3]. Group 1: Product Development and Innovation - The CSTM stent system is the world's first integrated arch branch reconstruction solution designed for complex aortic arch pathologies, addressing the challenges of traditional endovascular techniques [1][2]. - The product features a unique groove design that fits the anatomy of the arch, significantly reducing the risk of cerebral ischemia, and employs an integrated structure to prevent endoleaks while ensuring high branch patency rates [2][3]. - The company holds independent intellectual property rights for the product, which has already been successfully implanted in multiple clinical cases across Germany, Switzerland, Greece, and Hong Kong, receiving high recognition from international clinical experts [3]. Group 2: Clinical Research and Results - The feasibility study (FIM study) led by Professor Shu Chang completed enrollment of 10 patients in June 2023, showing no endoleaks and high patency rates at 12-month follow-up, validating the safety and effectiveness of the CSTM stent system [2]. - A subsequent prospective, multi-center clinical trial aims to enroll 103 patients across 25 authoritative centers, with 52 patients enrolled as of August 31, 2025, demonstrating a 100% technical success rate and a 1.92% all-cause mortality rate at 30 days post-operation [2]. - The absence of severe complications such as permanent paralysis or retrograde type A aortic dissection further supports the clinical value and application prospects of the CSTM stent system in aortic arch reconstruction [2]. Group 3: Market Impact and Future Outlook - The entry of the CSTM stent system into the special review procedure is expected to shorten the registration process and accelerate its market launch, benefiting patients with aortic arch aneurysms and ulcers [3]. - The anticipated market introduction will expand the company's product offerings and establish a comprehensive minimally invasive treatment solution for aortic diseases, covering key technical areas such as endovascular reconstruction of the arch branches, visceral branch, and iliac arteries [3].

Core Viewpoint - The company has received formal notification from the National Medical Products Administration confirming that its Concave Supra integrated arch branch reconstruction system (CSTM stent system) has entered the special review procedure for innovative medical devices, marking a significant advancement in minimally invasive treatment for complex aortic arch aneurysms and penetrating ulcers [1][3]. Group 1: Product Development and Innovation - The CSTM stent system is the world's first integrated solution for aortic arch branch reconstruction without brain ischemia, designed specifically for the complex anatomy of the aortic arch [1][2]. - The product has been developed in collaboration with Professor Shu Chang from the National Cardiovascular Center and has become the company's 17th product to enter the special review procedure [1][3]. Group 2: Clinical Research and Results - A feasibility study (FIM study) led by Professor Shu Chang included 10 patients and showed no internal leakage or adverse events after 12 months, validating the safety and effectiveness of the CSTM stent system [2]. - A subsequent prospective, multi-center clinical trial has enrolled 103 patients across 25 centers, with 52 patients enrolled as of August 31, 2025, demonstrating a 100% immediate technical success rate and a 1.92% all-cause mortality rate within 30 days [2]. Group 3: Market Potential and Strategic Outlook - The company holds independent intellectual property rights for the CSTM stent system, which has been successfully implanted in multiple cases in Germany, Switzerland, Greece, and Hong Kong, receiving high recognition from international clinical experts [3]. - The entry into the special review procedure is expected to shorten the registration process and accelerate the product's market launch, benefiting patients with aortic arch aneurysms and ulcers while expanding the company's product range [3].